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Clinical Trials and Novel Treatments

(IgG) and (IgM) were performed using Microwell ELISA from
Diagnostic Automation INC (USA).
Patients had the following endoscopic diagnosis: duodenal ulcer:
10; gastric ulcer, 2; nonulcer dyspepsia, 34; including gastritis, 23;
hiatal hernia, 2; biliary reflux, 2; nonabnormality, 7. The mean age
was 51 years with 26 men and 20 women. Sera were maintained
at −70 °C before being tested.

Among the 46 sera tested, 29 were positive (63.04%). The
prevalence of H. pylori infection in the symptomatic population of
La Habana is the same as reported for other developing countries.
These results indicate the importance for further studies to
identify factors influencing the prevalence in the Caribbean.
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Abstract no.: 11.01
Third-line Rescue Therapy with Levoﬂoxacin or
Rifabutin after Two Helicobacter pylori
Treatment Failures

Abstract no.: 11.02
Levoﬂoxacin/Azithromycin-Based Triple
Therapies as First-Line Treatment for
Helicobacter pylori Eradication

J. P. Gisbert, J. L. Gisbert, S. Marcos, R. Moreno-Otero
& J. M. Pajares

E. C. Nista, M. Candelli, R. Finizio, G. Cammarota,
G. Gasbarrini & A. Gasbarrini

La Princesa University Hospital, Madrid, Spain

Catholic University, Rome, Italy

Aim. In patients with a first eradication failure, a second (rescue)
therapy still fails in > 20% of the cases. Both rifabutin and
levofloxacin have been suggested to be effective in these refractory
cases. Our aim was to compare two rescue regimens based on
these antibiotics in patients with two consecutive eradication
failures.
Methods. Patients in whom a first treatment with omeprazoleclarithromycin-amoxicillin and a second trial with omeprazolebismuth-tetracycline-metronidazole (or ranitidine bismuth citrate
with these antibiotics) had failed, received 10 day treatment with
either rifabutin (150 mg b.i.d.) or levofloxacin (500 mg b.i.d.),
plus amoxicillin (1 g b.i.d.), and omeprazole (20 mg b.i.d.). Cure
rates were evaluated by 13C-urea breath test.
Results. Forty patients were included (mean age, 56 years, 36%
men; 19% peptic ulcer, and 81% functional dyspepsia): 20
received rifabutin and 20 levofloxacin. All the patients returned
for follow-up. Compliance in the rifabutin group was 100%. Four
patients in the levofloxacin group did not correctly take the
medication (in two cases as a result of adverse effects: myalgias
and rash). Side effects in the rifabutin and levofloxacin groups
were reported in 60% and 50% of the cases. Five patients (25%)
treated with rifabutin presented leucopenia, and six patients
(30%) treated with levofloxacin presented myalgias. Per-protocol
cure rates were 45% (95%CI, 26–66%) in the rifabutin group,
and 85% (64–95%) in the levofloxacin group (p < .01).
Intention-to-treat cure rates were, respectively, 45% (26–66%)
and 81% (57–93%) (p < .05).
Conclusions. After two previous Helicobacter pylori eradication
failures, 10-day triple levofloxacin-based rescue regimen is more
effective than the same regimen with rifabutin.

Background. The failure of anti-Helicobacter pylori therapies is the
result of antibiotic resistance. Levofloxacin and azithromycin are
administrable in single daily dose and could increase patients
compliance. The aim of the study is to compare the efficacy of a
3- and 7-day levofloxacin/azithromycin-based regimen against
standard therapy.
Material and Methods. Ninenty H. pylori-positive patients were
randomized to receive: group A (30 patients), levofloxacin,
azithromycin, and esomeprazole for 3 days; group B (30 patients),
levofloxacin, azithromycin, and esomeprazole for 7 days; group C
(30 patients) clarythromicin, amoxicillin, and esomeprazole. H.
pylori status was rechecked by 13C-UBT 6 weeks after end of
therapies.
Results. H. pylori eradication rate in group A was 86.7% (26/30
patients), 93.3% (28/30 patients) in group B, 70% (21/30) in
group C. Eradication rate of 7-day levofloxacin/azithromycinbased triple therapy was significantly higher than that observed
using standard triple therapy (93.3% versus 70%; p < .05). A
trend, even if not statistically significant in higher eradication rate,
was observed using 3-day levofloxacin/azithromycin-based triple
therapy compared to standard therapy (86.7% versus 70%
p = .06). Incidence of side effects was lower in groups A and B
than in group C. Moreover, prevalence of side effects resulted
higher in the group B than in group A.
Conclusions. According to the present data, a 7-day levofloxacin/
azithromycin-based triple therapy may be considered a highly
effective therapy for H. pylori eradication. Interestingly, a short
course of treatment antibiotics (3-day levofloxacin/azithromycin)
may be suggested to patients with high incidence of side effect
instead of standard treatment.
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Abstract no.: 11.03
Ranitidine Bismuth Citrate- Versus Levoﬂoxacinbased Triple Rescue Therapy after Helicobacter
pylori Treatment Failure
J. P. Gisbert, J. L. Gisbert, S. Marcos, R. Moreno-Otero
& J. M. Pajares
La Princesa University Hospital, Madrid, Spain
Aim. Ranitidine bismuth citrate (RBC)-based rescue regimen has
been demonstrated to be an alternative to quadruple rescue
therapy after Helicobacter pylori eradication failure. On the other
hand, levofloxacin has remarkable activity in vitro against H. pylori.
Our aim was to compare, by a randomized trial, two different 7day triple rescue regimens based on RBC or levofloxacin.
Methods. Patients in whom a first eradication trial with
omeprazole-clarithromycin-amoxicillin
had
failed
were
randomized, in this single-centre study, to receive 7-day
treatment with: (1) RBC (400 mg b.i.d.), tetracycline (500 mg
q.i.d.), and metronidazole (250 mg q.i.d.), or (2) levofloxacin
(500 mg b.i.d.), amoxicillin (1 g b.i.d.), and omeprazole (20 mg
b.i.d.). Cure rates were evaluated by 13C-urea breath test.
Results. One hundred patients were included (mean age, 47
years, 34% men; 18% peptic ulcer, and 82% functional
dyspepsia); 50 received the RBC regimen, and 50 the levofloxacin
one. Groups were comparable in terms of demographic variables.
Two percent of the patients (one in each group) did not return for
follow-up. Compliance was similar in both groups (90% took
correctly all the medications). Side effects (only mild/moderate)
in the two groups were also comparable (38% with the RBC
regimen and 36% with the levofloxacin). Per-protocol cure rates
were 69% (95% CI, 54–80%) in the RBC group and 71% (57–
82%) in the levofloxacin group. Intention-to-treat cure rates were,
respectively, 68% (59–79%) and 68% (59–79%) (nonstatistically
significant differences).
Conclusions. Both 7-day RBC- and levofloxacin-based rescue
regimens represent effective alternatives to quadruple therapy in
patients with omeprazole-clarithromycin-amoxicillin failure.
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Abstract no.: 11.04
An Updated Meta-Analysis of Different
Duration of First-Line, Clarithromycin-Based
Triple Therapy for Helicobacter pylori Infection
L. Fuccio, M. E. Minardi, R. M. Zagari & F. Bazzoli
Department of Internal Medicine and Gastroenterology, Bologna, Italy
Aim. To evaluate the efficacy of first line, clarithromycin-based
triple therapy of different length for treating Helicobacter pylori
infection by an updated meta-analysis of comparative trials.
Methods. Computer-assisted and manual bibliographical searches
were performed through May 2006. Randomized controlled trials
comparing different length of identical triple therapies were included.
Study quality was assessed using the Jadad scale. Meta-analysis was
performed combining the risk ratio (RR) of the individual studies.
Results. Twenty-four RCTs were included in the analysis: 10 trials
(six high-quality trials) comparing 7 versus 10 days (1098 versus
1064 patients); 16 trials (five high-quality trials) comparing 7
versus 14 days (1416 versus 1386 patients). The majority part of
the studies was performed in Europe (16), then in Asia (4), North

America (3), and Africa. The meta-analysis showed superiority of
prolongation the duration of therapy: 7 versus 10 days relative RR
of 0.95 (95% CI = 0.91–0.99) with an NNT of 28; 7 versus 14 days
relative RR of 0.91 (0.88–0.95) with a NNT of 14. This difference
reached, in both cases (7 versus 10; 7 versus 14), statistical significance.
A meta-analysis performed considering only high-quality studies
showed similar efficacy between different length of therapy: 7 versus
10 days relative RR of 0.95 (95% CI: 0.90 –1.00); 7 versus 14 days
relative RR of 0.98 (0.92–1.04), lacking statistical significant difference.
Conclusion. Increasing the length of first-line, clarithromycinbased triple therapies beyond 7 days does not improve treatment
efficacy when only high-quality trials are considered into metaanalyses. More high-quality studies, especially from developing
countries, are needed.
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Abstract no.: 11.05
Eradication of Helicobacter pylori Infection
with Two Triple-Therapy Regimes of 7, 10, and
14 days; Four Years Experience
M. Katicic, M. Ticak, M. Prskalo, S. NaumovskiMihalic, T. Filipec-Kanizaj, B. Skurla, B. Sabaric,
V. Colic-Cvrlje & B. Papa
University Hospital Merkur, Zagreb, Croatia
Aim. The efficacy of the most frequently used triple-therapy
regimes (pantoprazole 40 mg, amoxicillin 1 g, metronidazole
500 mg, or clarithromycin 500 mg b.i.d.) of 7, 10, and 14 days
duration, was investigated in 596 Croatian patients with gastric
(GU), duodenal ulcer (DU), and nonulcer dyspepsia (NUD),
treated from January 2002 until December 2005.
Methods. One hundred seventy-two GU (M/F 100/72), 282 DU
(M/F 176/106), and 138 NUD (M/F 59/79), Helicobacter pyloripositive patients, underwent endoscopy with histology and culture
at the beginning and 4–8 weeks after the end of the treatment.
They were randomly assigned to six treatments groups: PAM
groups, A for 14 days (n = 58), B for 10 days (n = 118), C for 7
days (n = 122); PAC groups, D for 14 days (n = 58), E for 10 days
(n = 118), F for 7 days (n = 122). Five hundred sixty patients
(94%) completed the study.
Results. The results of H. pylori eradications are presented in Table 1.
Conclusion. In all groups (7, 10, 14 days), the triple-therapy
containing clarithromycin had greater H. pylori eradication rate
than that containing metronidazole. The eradication rate exceeding
80% in ITT and 90% in PP calculation was achieved only by 14
and 10 days of PAC and only by 14 days of PAM. No statistical
differences were found among all six groups in ulcer-healing rate,
and clinical improvement rate was slightly higher in patients with
ulcers than in patients with nonulcer dyspepsia. (*p < .05 was
found between A and C groups, and between D and F groups).

A
B
C
D
E
F

Eradication rate (ITT)

Eradication rate (PP)

55/58 (95%)*
98/119 (83%)
92/122 (75%)*
54/58 (93%)*
93/118 (79%)
90/122 (74%)

55/56 (98%)*
98/109 (90%)
92/113 (81%)*
54/57 (95%)*
93/112 (83%)
90/113 (80%)*
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Abstract no.: 11.06
Impact of Helicobacter pylori Eradication
Regimen Tailored for Clarithromycin
Susceptibility in Japan
T. Kawai,* T. Yamagishi,* M. Kataoka,* R. Tamura,†
E. Rimbara,† N. Noguchi† & M. Sasatsu†
*Endoscopy Center, Tokyo Medical University Hospital, Tokyo,
Japan, †Tokyo University of Phamacy and Life Science, Tokyo, Japan
Background. Decrease in eradication rate of proton pump
inhibitor (PPI)/AC therapy for Helicobacter pylori was recognized. It
is mainly induced by increase in clarithromycin (CAM)-resistant
H. pylori. It is reported that PPI+AMPC+MNZ (PPI/AM) therapy
have high eradication rate for CAM-resistant H. pylori. We
investigated the usefulness of the regimens tailored for CAMsusceptibility using human feces.
Method. Fifty-four H. pylori-positive patients were recruited. We
divided two groups. In one group, patients received PPI/AC
(LPZ 60 mg + AMPC 1500 mg + CAM 800 mg 1 week) regimen
without investigation into CAM susceptibility before treatment
(control group). In another group, patients received PPI/AC
regimen for CAM susceptibility (S), or PPI/AM regimen (RPZ 20 mg
+ AMPC 1500 mg + MNZ 500 mg 1 week) for CAM resistance (R)
with investigation into CAM susceptibility before treatment
(tailored group). CAM susceptibility test was conducted using
patient feces by restriction fragment-length polymorphism–
nested polymerase chain reaction (Rimbara E, et al. Curr Microbiol
2005; 51: 1–5).
Result. Eradication rates (ITT, intention to treat) were 92.6% and
66.7% in the tailored group and control group, respectively, with
this difference being significant. Moreover, eradication rates were
90.0% and 94.1% for the PPI/AC regimen for CAM-S and PPI/
AM regimen for CAM-R in tailored group, respectively, with no
significant difference
Conclusion. Tailored H. pylori-eradication therapy for CAMsusceptibility is very useful regimen in recently Japan with CAM
resistance rate more than 20%.
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Abstract no.: 11.07
Third-line Rescue Therapy with Levoﬂoxacin
after Two Helicobacter pylori Treatment
Failures
J. P. Gisbert,* M. Castro-Fernandez,† F. Bermejo,‡
A. Perez-Aisa,§ J. Ducons,¶ M. Fernandez-Bermejo,**
F. Bory,†† A. Cosme,‡‡ L. M. Benito,§§ L. LopezRivas,¶¶ E. Lamas,† M. Pabón† & D. Olivares*
*La Princesa University Hospital, Madrid, Spain, †Valme Hospital,
Sevilla, Spain, ‡Fuenlabrada Hospital, Madrid, Spain, §Costa del
Sol Hospital, Malaga, Spain, ¶San Jorge Hospital, Huesca, Spain,
San Pedro de Alcantara Hospital, Caceres, Spain, ††Del Mar
Hospital, Barcelona, Spain, ‡‡Donostia Hospital, San Sebastian,
Spain, §§Virgen del Toro Hospital, Menorca, Spain, ¶¶San Agustín
Hospital, Asturias, Spain
Aim. Eradication therapy with proton pump inhibitor, clarithromycin, and amoxicillin fails in a considerable number of cases. A
rescue therapy still fails in more that 20% of the cases. Our aim
was to evaluate the efficacy and tolerability of a third-line

levofloxacin-based regimen in patients with two consecutive
Helicobacter pylori eradication failures.
Methods. Design: Prospective multicenter study. Patients: In
whom a first treatment with omeprazole-clarithromycinamoxicillin and a second with omeprazole-bismuth-tetracyclinemetronidazole (or ranitidine bismuth citrate with these antibiotics)
had failed. Intervention: A third eradication regimen with levofloxacin (500 mg b.i.d.), amoxicillin (1 g b.i.d.), and omeprazole
(20 mg b.i.d.) was prescribed for 10 days. Outcome: Eradication
was confirmed with 13C-urea breath test 4–8 weeks after therapy.
Results. One hundred patients were initially included, and nine
were lost for follow-up. All patients but five took all the medications
correctly. Per-protocol and intention-to-treat eradication rates
were 66% (95% CI = 56–75%) and 60% (50–70%). Adverse
effects were reported in 25% of the patients, mainly including
metallic taste (8%), nausea (8%), myalgia/arthralgia (5%), and
diarrhea (4%); none of them were severe.
Conclusion. Levofloxacin-based rescue therapy constitutes an
encouraging empirical third-line strategy after multiple previous
H. pylori eradication failures with key antibiotics such as
amoxicillin, clarithromycin, metronidazole, and tetracycline.
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Abstract no.: 11.08
Reinfection of Helicobacter pylori in Type 1 Young
Diabetic Patients: A Long-Term Follow-Up Study
M. Candelli, D. Rigante, E. C. Nista, A. Schiavino,
G. Marietti, M. A. Zocco, G. Pignataro, G. Masi,
S. Petrucci, N. Gentiloni Silveri, G. Gasbarrini &
A. Gasbarrini
Catholic University, Rome, Italy
Introduction. Several studies have demonstrated that Helicobacter
pylori eradication does not affect metabolic control in type 1
diabetic patients. The prevalence of H. pylori infection in diabetic
patients seems to be higher than in general population and adult
patients with diabetes present higher re-infection rates than
dyspeptic patients. Aims of our study were to evaluate a longterm H. pylori re-infection rate after having performed the
eradicating protocol in a group of young diabetic patients.
Methods. We enrolled 75 patients affected by type 1 diabetes and
99 healthy controls in which we had evaluated H. pylori infection
prevalence and performed an eradicating therapy in H. pyloripositive patients. In all recruited patients we have re-investigated
H. pylori presence by means of 13C-urea breath test and metabolic
control through the evaluation of glycosylated hemoglobin A
levels and daily insulin requirement.
Results. The re-infection rate was higher in patients with diabetes
than in healthy controls of similar age, gender, and socioeconomic
status (33.3% versus 4.5%; p < .05). H. pylori infection appeared to
be related to socioeconomic factors evaluated by means of annual
income. Metabolic control was not affected by H. pylori status.
Conclusion. No association has been found between H. pylori
gastric infection and type 1 diabetes mellitus; young diabetic
patients are at higher risk to present a re-infection if compared
with healthy controls. The test-and-treat strategy does not appear
useful in these patients and H. pylori eradication should be taken
into account case by case by the physician.
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Abstract no.: 11.09
Levoﬂoxacin-based Rescue Regimens after
Helicobacter pylori Treatment Failure:
Systematic Review and Meta-Analysis
J. P. Gisbert & F. de la Morena
La Princesa University Hospital, Madrid, Spain
Background. A quadruple therapy has been generally recommended as rescue regimen for Helicobacter pylori eradication
failures.
Objective. To systematically review the efficacy and tolerance of
levofloxacin-based rescue regimen and to conduct a meta-analysis
of studies comparing it with the quadruple therapy for eradication
failures.
Methods. Selection of studies: Levofloxacin-based rescue
regimens. For the meta-analysis, randomized controlled trials
comparing levofloxacin-based and quadruple regimens were
selected. Search strategy: Electronic and manual bibliographic
searches. Study quality: Independently assessed by two reviewers.
Data synthesis: “Intention-to-treat” H. pylori eradication rate.
Results. Mean eradication rate with levofloxacin was 80%. Tenday regimens were more effective than 7-day combinations (81%
versus 73%; p < .01). The meta-analysis showed better results
with levofloxacin than with the quadruple combination (81%
versus 70%; OR = 1.80; 95% CI = 0.94–3.46). This difference
reached statistical significance, and heterogeneity markedly
decreased when a single outlier study was excluded or when only
high-quality studies were considered. Incidence of adverse effects,
and severe adverse effects in particular with levofloxacin was
18% and 3%, respectively. Levofloxacin had less adverse effects
(19% versus 44%; OR = 0.27; 95% CI = 0.16 – 0.46) and less severe
adverse effects (0.8% versus 8.4%; OR = 0.20; 95% CI = 0.06 –
0.67) than the quadruple regimen.
Conclusion. After H. pylori eradication failure, levofloxacinbased rescue regimen is more effective and better tolerated than
the generally recommended quadruple therapy. A 10-day
combination of levofloxacin-amoxicillin proton pump inhibitor
constitutes an encouraging second-line alternative.
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Abstract no.: 11.10
Clinical Application of He-Ne Laser for
Eradication of Helicobacter pylori
L. B. Lazebnik,* S. G. Khomeriki* & N. M. Khomeriki†
*Central Research Institute of Gastroenterology, Moscow, Russian
Federation, †Pushchino Medical Center, Moscow Region, Russian
Federation
The irradiation of low-power laser is followed by significant
reduction of the bacterial viability. Resistance of Helicobacter pylori
to metronidazole promotes enhanced sensibility to laser irradiation.
The purpose of the study was to eradicate H. pylori by the laser
irradiation after failure of standard drug therapies and in patients
with allergy to antibiotics.
Methods. Thirty patients with proven H. pylori infection were
selected for photodynamic therapy. Fifteen of them had clinical
improvement after courses of triple and/or quadruple therapies,
but had not eradication of H. pylori. Ten patients had not
completed triple therapy because of allergy to antibiotics.

Methylene blue was given to patients as photosensitizer an hour
before endoscopy. The quartz light conductor was put through
biopsy channel of the endoscope. Gastric mucosa was irradiated
by He-Ne laser (λ = 633 nm) with 25 megawatts output power
during 10–15 minutes. The course consisted of three procedures
every other day. Gastric biopsy samples from each patient were
sent for culture and histology.
Results. The metronidazole-resistant strains were found in 16
patients (53.3%). The laser irradiation does not alter gastric
epithelial cells. All patients completed photodynamic therapy and
underwent control endoscopy after 4 weeks. The therapy success
was confirmed in 27 patients by histology and the rapid urease
test.
Conclusion. The photodynamic therapy with He-Ne laser may
be used as alternative therapy for H. pylori eradication in patients
with allergy to antibiotics and after standard treatment failures.
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Abstract no.: 11.11
Novel Approach to Eradication of Helicobacter
pylori: Carbonic Anhydrase Inhibition
Interferes with Acid Acclimatization, Studies In
Vitro and In Vivo
I. T. Padol,* G. Sachs,† D. R. Scott† & R. H. Hunt*
*McMaster University, Hamilton, Ontario, Hamilton, ON, Canada,
†University of California at Los Angeles, Los Angeles, CA, United
States
As Helicobacter pylori increasingly acquire resistance to antibiotics new eradication treatments are needed. Periplasmic
alpha-carbonic anhydrase plays an important role in enabling
acclimatization of H. pylori to an acidic milieu, prompting the
question of targeting this mechanism with selective eradication
therapy. This study aimed to determine the ability and conditions
of Diamox, a carbonic anhydrase inhibitor, to interfere with
survival of H. pylori and the feasibility of eradication treatment.
In vitro methods included exposure of the wild type and an
α-carbonic anhydrase knockout H. pylori organism to Diamox
and assessment of survival. For in vivo studies, four groups of
Mongolian gerbils were infected with H. pylori; group I was treated
IP once daily with Diamox 50 mg/kg for 7 days, group II received
Diamox 50 mg/kg by gavage once daily for 5 days, and two
infected groups served as controls. In vitro Diamox impaired
survival of H. pylori at pH = 2.0–2.5 by approximately 1–2 log scale
depending on experimental conditions. Gerbils treated with
Diamox IP showed reduced bacterial scores in antrum, fundus,
and cardia and delayed positive CLO tests for H. pylori, which
suggest compromised acid acclimatization of the organism.
Eradication rate for this treatment regimen was low 12.5% (2 out
of 16 gerbils). However, gerbils treated with Diamox by oral
gavage had > 90% reduction in colony-forming unit of H. pylori
recovered from the stomachs, suggesting effective eradication for
this route of drug administration. In conclusion, the acidic milieu
facilitates the antimicrobial properties of a carbonic anhydrase
inhibitor for H. pylori offering opportunity for developing new
eradication regimens.
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Abstract no.: 11.12
The Effect of Novel and Current Helicobacter
pylori Eradication Regimes on Gastric Emptying
S. Kritas,*† M. A. F. Campbell,*† Y. Kolev,*†
L. M. Stevenson‡ & R. N. Butler*
*Centre for Paediatric and Adolescent Gastroenterology, CYWHS,
North Adelaide, SA, Australia, †Numico Research Australia Pty
Ltd, Oakden SA, Australia, ‡Hort Research, Auckland, New
Zealand
Background. Although antibiotic therapy is the first line of
therapy for Helicobacter pylori, there is a global need for new
therapies. However, the potential effect of current and new
treatments on gastric motility is unknown.
Aim. To assess the effect of infection and treatment by current
and novel regimes on gastric motility in H. pylori infected mice.
Methods. Fasted mice (n = 15) were gavaged 0.1 mL nutrient
solution (Intralipid) containing 1 µL/mL 13C-octanoic acid for the
assessment of gastric emptying (GE). Breath samples were
collected at intervals before and after ingestion of the solution and
analyzed for 13CO2 content. Gastric half emptying times (t1/2) were
calculated from the resulting 13CO2 excretion curves. The GE
breath test was performed at pre-infection, 4 weeks after H. pylori
infection and after 14 days of treatment. Treatment groups included
amoxycillin, metronidazole, hyperimmune bovine colostrum
(HBC)/neoadjuvant chemotherapy (NAC), HBC/NAC +
amoxycillin, HBC/NAC + metronidazole, and triple therapy
(amoxycillin, metronidazole, omeprazole).
Results. H. pylori infection did not alter GE. However, after 14
days of treatment, all treatments except metronidazole and
HBC/NAC + metronidazole significantly slowed gastric emptying.
(Table 1)
Conclusions. Four-week H. pylori infection does not affect gastric
motility in mice. However, 14-day treatment does have an impact
on GE. Further studies should assess this effect in patients and
determine if the effect persists after cessation of H. pylori
eradication therapy.
Table 1.
Gastric half emptying times (t1/2) (min) median [IQR]
Treatments

Pre-infection

4 weeks infection

Post-treatment

Amoxycillin
Metronidazole
HBC/NAC
HBC/NAC+amox
HBC/NAC+metro
Triple Therapy
Not infected

26 [20, 30]
27 [22, 30]
33 [30, 44]
27 [25, 32]
31 [24, 37]
27 [23, 35]
27 [18, 32]

27 [22, 31]
28 [23, 33]
29 [26, 33]
25 [23, 31]
38 [33, 43]
34 [33, 43]
30 [25, 38]

40 [36, 51]†‡
36 [27, 40]
49 [39, 67]†‡
36 [30, 42]†‡
33 [28, 40]
55 [47, 65]†‡
40 [34, 47]†

†p < .05 compared to pre-infection, ‡p < .05 compared to 4 weeks
infection.

Abstract no.: 11.13
The Efﬁcacy of One-week Low-dose Triple
Therapy Containing Pantoprazole (40 mg b.i.d.),
Amoxicillin (750 mg b.i.d.) and Clarithromycin
(250 mg b.i.d.) for Helicobacter pylori
Eradication in Korea
W. Paik* & D. Lee†
*Department of Internal Medicine and Liver Research Institute,
Seoul National University Hospital, Seoul, Republic of Korea,
†Department of Internal Medicine, Seoul National University
Bundang Hospital, Korea, Seoul, Republic of Korea
Background/Aims. The recommended regimen of Helicobacter
pylori eradication in Japan is standard dose proton pump inhibitor
(PPI) b.i.d. + amoxicillin 750 mg b.i.d. + clarithromycin 200–
400 mg b.i.d. for 7 days. In Korea, the recommended regimen
of H. pylori eradication is standard-dose PPI b.i.d. + amoxicillin
1000 mg b.i.d. + clarithromycin 500 mg b.i.d. for 7 days. We could
expect patients’ good compliance, decrease of drug side effects,
and cost reduction by using low-dose therapy. But the efficacy of
low-dose therapy is questionable in Korea. In this study, we
compared the efficacy of low-dose therapy with standard-dose
therapy.
Methods. Four hundred eighty patients who visited Seoul
National Unversity Bundang Hospital during January 2005 to
April 2006 with documented H. pylori infection were enrolled.
Seven patients were excluded because of malignancy and drug
history. One hundred eighty-two patients received low-dose triple
therapy (pantoprazole 40 mg b.i.d. + amoxicillin 750 mg b.i.d. +
clarithromycin 250 mg b.i.d.) and 291 patients received standarddose triple therapy (pantoprazole 40 mg b.i.d. + amoxicillin
1000 mg b.i.d. + clarithromycin 500 mg b.i.d.). Eradication was
confirmed by UBT 1 month after eradication.
Results. The two groups were similar with regard to all clinical
characteristics. The H. pylori eradication rates was 74.2% (135/
182) in low-dose triple therapy group, and was 77.3% (225/291)
in standard-dose triple therapy group. There was no significant
difference of H. pylori eradication rates between these two groups
(p = .435). There was no serious side effect in both group.
Conclusions. The efficacy of low-dose triple therapy is similar to
standard-dose triple therapy. These findings suggest that low-dose
triple therapy could be another effective regimen considering cost
benefit in Korea.
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Abstract no.: 11.14
Comparison of Two and Four Times a Day
Amoxicillin with Proton Pump Inhibitor,
Clarithromycin for Helicobacter pylori
Infection: A Randomized Study
J. Koo, S. Lee, S. Kim, S. Jung, H. Yim, H. Lee, J. Choi,
C. Kim & H. Ryu
Institutes of Digestive Diseases and Nutrition, Department of
Internal Medicine, Korea University College of Medicine, Seoul,
Republic of Korea
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Background. A proton pump inhibitor (PPI)-based triple therapy
with clarithromycin and amoxicillin is now a standard regimen
for Helicobacter pylori eradication therapy. Most H. pylori are
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susceptible to amoxicillin, an important component of many
combination therapies for H. pylori eradication. Amoxicillin has
time-dependent bactericidal activity for against H. pylori.
Aim. To evaluate and compare the efficacy of two and four times
daily amoxicillin regimens for treatment of H. pylori in a
randomized study.
Methods. One hundred sixty-three patients with peptic ulcer
and H. pylori infection confirmed by endoscopy and histology
were eligible to this study. H. pylori infection was proved by
histology or rapid urease test. Patients randomly assigned to one
of the two regimens: amoxicillin 1.0 g b.i.d. (group A, n = 90) or
amoxicillin 500 mg q.i.d. (group B, n = 73) with clarithromycin
500 mg b.i.d. and omeprazol 20 mg b.i.d. for 2 weeks. All patients
were asked to return at the end of treatment to access compliance
and adverse events. The eradication rates of H. pylori were
evaluated by repeated endoscopy or 13C-urea-breath test 4 weeks
after completion of treatment.
Results. One hundred fifty-four patients completed the trial (86
group A, 68 group B). The eradication rates were 91.1% in group
A, 89.0% in group B (p > .05). Compliances were fairly good in
both groups. Side effects in two groups were generally mild and
nine discontinued treatment because of adverse effects.
Conclusion. Both the two and the four times daily amoxicillin regimens are equally effective and safe for H. pylori eradication therapies.

Original Article
11
xxxxx

Abstract no.: 11.15
Food and Nutrient Intakes in Functional
Dyspepsia Before and After Helicobacter pylori
Eradication.
J. Ciok, M. Sobczak & A. Salwerowicz
Food and Nutrition Institute, Warsaw, Poland
Background. In spite of the fact that functional dyspepsia is a
common disease, the number of studies evaluating nutritional
patterns in those patients is very limited. The dietary patterns before
after Helicobacter pylori eradication were never studied. The aim of
the study was to evaluate nutritional habits in the group of patients
with functional dyspepsia and to test if H. pylori eradication
changes them.
Material and Methods. Fifty-four patients with functional
dyspepsia and present H. pylori infection were submitted to the
study. All of them underwent H. pylori eradication.
The 3-day diet history was used to obtain dietary assessment. A
dietary questionnaire was filled two times: before eradication treatment and about 1 month (4 – 6 weeks) after finishing the treatment.
Results. The patients’ diet does not correspond to dietary
recommendations. Low energy intake, carbohydrate, fiber,
vitamins (thiamine, riboflavin, vitamin B6, folic acid), minerals
(calcium, potassium, iron, zinc, and copper), and high fat
consumption were found. No significant dietary changes after
successful H. pylori eradication treatment were found. The only
exception was a certain drop in polyunsaturated fatty acids.
Summary. Diet of patients with functional dyspepsia is a
nutritionally imbalance diet that cannot respond to many
nutritional recommendations.
After successful H. pylori eradication, no specific dietary changes
were found. H. pylori eradication has got no influence on dietary
habits in the group of dyspeptic patients.

Abstract no.: 11.16
Helicobacter pylori First-Line Treatment and
Rescue Options in Patients Allergic to Penicillin
J. P. Gisbert, J. L. Gisbert, S. Marcos, D. Olivares &
J. M. Pajares
La Princesa University Hospital, Madrid, Spain
Aim. To assess the efficacy and tolerability of Helicobacter pylori
first-line treatment and rescue options in patients allergic to
penicillin.
Methods. Patients: Prospective single-center study including
40 consecutive treatments administered to patients allergic to
penicillin. Therapy regimens: First-line (12 patients): omeprazole,
clarithromycin, and metronidazole for 7 days. Second-line (17
patients): ranitidine bismuth citrate, tetracycline, and metronidazole
for 7 days. Third-line (9 patients): rifabutin, clarithromycin, and
omeprazole for 10 days. Fourth-line (2 patients): levofloxacin,
clarithromycin, and omeprazole for 10 days. Outcome variable:
a negative 13C-urea breath test 8 weeks after completion of
treatment.
Results. Per-protocol/intention-to-treat eradication rates were
first-line regimen, 64%/58%; second-line regimen (ranitidinebismuth-citrate), 53%/47%; third-line regimen (rifabutin), 17%/
11%; fourth-line regimen (levofloxacin), 100%/100%. Compliance
with treatment was generally good, except with the rifabutinbased regimen, which presented adverse effects in 89% of the
patients, including four cases of myelotoxicity.
Conclusion. H. pylori-infected patients allergic to penicillin may
be treated with a first-line treatment combining PPI, clarithromycin,
and metronidazole. Rescue options may include a regimen with
ranitidine bismuth citrate, tetracycline, and metronidazole. A
levofloxacin-based rescue regimen (with PPI and clarithromycin)
may also represent an alternative, even when two or more consecutive eradication treatments have previously failed. However,
rifabutin-clarithromycin-PPI regimen is ineffective and poorly
tolerated.
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Abstract no.: 11.17
The Prediction of Ulcer/Erosion Relapse after
Helicobacter pylori Eradication: a One-Year
Follow-up Study
Y. B. Shvydkyy, M. R. Gzhegotsky, O. S. Zayachkivska,
I. M. Tumak & V. I. Vdovychenko
Danylo Halytsky Lviv National Medical University, Lviv, Ukraine
We estimated the long-term effects of successful Helicobacter
pylori eradication on relapse of ulcers/erosions in duodenal ulcer
patients. One hundred eight adult patients (71 men, 37 women,
16 –75 years) were enrolled in the study. The endoscopy, rapid
urease test (RUT), histology of gastric mucosa specimens according
to the updated Sydney system standards were performed for
determination the H. pylori status and healing of mucosa defects
before treatment and at 4 –6 weeks and 1 year after usual triple
therapy.
The H. pylori eradication rate was 90.7% at 4 –6 weeks after
triple therapy; however, complete healing of ulcer and concurrent
gastroduodenal erosions was in 67.5% cases. In a 1-year

xxxxx
Original Article
11

© 2006 The Authors

390

Journal compilation © 2006 Blackwell Publishing Ltd, Helicobacter 11: 321–415

Clinical Trials and Novel Treatments

prospective study 41 (41.8%), patients were free from H. pylori
infection, among them were 13 (31.7%) cases of relapse of ulcers/
erosions, predominantly without clinical symptoms. The higher
grade of atrophy of fundal mucosa before treatment, the presence
of residual ulcers or erosions, higher grade of antral mucosa
infiltration by mononuclear cells, and lower grade of fundal
mucosa infiltration by polymorphonuclear cells at 4–6 weeks after
H. pylori eradication were associated with the presence of ulcers or
erosions in the 1-year follow-up after H. pylori eradication
(p < .05, Fisher exact test for contingency tables, Mann–Whitney
U-test for semiquantitative characteristics). There were marginally
significant association of disease duration > 5 years with relapse
of gastroduodenal mucosal defects 1 year later (p = .095).
Recognized predictor factors witness the high risk of silent ulcer
recurrence after successful treatment of H. pylori, the group of
high risk needed the prolonged treatment (PPI, mucoprotectors)
and endoscopy controls.
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Abstract no.: 11.18
Intragastric Balloon Tolerance is Independent
of Helicobacter pylori Status in Patients with
Morbid Obesity
N. G. Mathou, K. D. Paraskeva, K. J. Zografos &
J. A. Karagiannis
Gastroenterology Unit, “Agia Olga” Hospital, Athens, Greece
Endoscopic intragastric balloon consists a method for weight loss.
However, most patients experience poor balloon tolerance. It has
not studied if the presence of Helicobacter pylori infection is a factor
affecting tolerability.
Thirty-three patients (median body mass index, 38.1), 23
women, 10 men, age range 20–65 years were studied. In all
patients, an intragastric balloon (INAMED, USA) was inserted
endoscopically and was filled up to a median volume of 550 mL.
H. pylori status was confirmed during screening endoscopy (rapid
urease test plus histology). Exclusion criteria were peptic ulcer,
severe gastritis, or chronic nonsteroidal anti-inflammatory drug
use. All patients were followed up daily in the first 7 days and
monthly thereafter up to removal (6 months later) by a standard
questionnaire. Patients were allowed to on-demand H2-RA/PPI’s
and/or prokinetics. Nausea and/or vomiting and/or crampy epigastric
pain were characterized as mild to moderate (nausea, vomiting
< 10/day, duration < 10 days and/or pain without necessitating
further management) or severe (intractable nausea and/or vomiting
> 10/day, duration > 10 days and/or severe pain necessitating
further management and/or premature removal of the balloon).
Fourtenn patients were H. pylori positive (42.4%) whereas
19 were negative (57.6%). All patients, independently to their
H. pylori status, experienced mild to moderate symptoms with
a mean duration of 2 days. Seven (21%) experienced severe
symptoms requiring further management (three H. pylori positive,
four H. pylori negative) and in four of them (12%) the balloon
had to be removed within 1 month (three H. pylori negative, one
H. pylori positive). These findings were not statistically significant,
against or for, H. pylori status.
Therefore, H. pylori eradication is not justified prior to balloon
insertion.

Abstract no.: 11.19
Use of Bovine Antibodies-Based Oral
Immunotherapy for Eradication of Helicobacter
pylori in a Placebo-Controlled Clinical Trial
A. C. de Vries,* C. M. Dierikx,* J. G. Kusters,*
H. Suzuki,† P. B. F. Mensink* & E. J. Kuipers*
*Erasmus MC, University Medical Center, Rotterdam, The
Netherlands, †Keio University School of Medicine, Tokyo, Japan
Antibiotics-based regimens are frequently used for treatment of
Helicobacter pylori infections. However, predominantly resulting
from antimicrobial resistance and poor patient compliance,
antibiotic-based eradication fails in 15 –40% of patients. Passive
immunization against H. pylori with orally administered bovine
antibodies was successful in animal studies, and may thus serve as
an alternative therapy in humans. In this study, its potential is
investigated in a clinical trial.
Polyclonal antibodies (sIgA) were raised in milk of dairy cows
by nasal and supra-mammary lymph node immunizations during
lactation. Cows were immunized with a mix of clinical H. pylori
isolates. Specific anti-H. pylori sIgA milk titers were measured by
enzyme-linked immunosorbent assay. The milk was processed
into a whey protein concentrate (WPC). These preparations were
first tested for their ability to reduce adhesion of H. pylori to gastric
biopsies.
To study the efficacy and safety of this WPC product, a doubleblind, placebo-controlled randomized clinical trial was designed.
In this study, 15 patients will be treated with the WPC product and
15 with placebo during 4 weeks. At this moment, 10 patients are
included in this ongoing study. Preliminary observations showed
no adverse effects of medication. The efficacy is evaluated as
reduction in intragastric H. pylori colonization density as determined
by UBT, histology, and culture. All outcome measures are
evaluated on days 0 and 29 after start of treatment, and on day 56,
UBT and blood tests are repeated.
Data from this study will contribute to the development of new
therapeutic or preventive strategies for H. pylori infection, without
the adverse effects of antibiotic treatment.

Original Article
11
xxxxx

Abstract no.: 11.20
Triple Therapy for Helicobacter pylori Infection
in Patients Presenting to a Tertiary Care Center
in Pakistan
S. Abid, J. Yakoob, W. Jafri, Z. Abbas & K. Mumtaz
Aga Khan, Karachi, Pakistan
Aim. To determine the eradication rate of Helicobacter pylori
infection in patients presenting to a tertiary care center.
Methodology. Patients presenting with symptoms and having an
endoscopy (EGD) were enrolled from January 2005 to March
2006. 14C-urea breath test (14C-UBT), rapid urease test (RUT),
histopathology, culture, and sensitivity were performed. Antibiotic
susceptibility was determined by disk diffusion test. Triple therapy
with proton pump inhibitor 20 mg b.i.d., clarithromycin 500 mg
b.i.d., and amoxicillin 1 g b.i.d. was prescribed for 10 days.
Eradication of H. pylori infection was confirmed 4 weeks after
therapy by 14C-UBT.
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Results. Of 80 patients, 56 (68%) were male, age range 15 –76
years, and mean age 45 years. The presenting symptoms were
abdominal pain in 54 (67%), vomiting 16 (20%), and nausea 10
(13%). EGD showed mucosal erythema 76 (95%) and duodenal
ulcer in 4 (5%). Histopathology demonstrated that H. pylori
associated moderate gastritis in 36 (45%) and mild gastritis in
44 (55%). Antibiotic susceptibility was determined in 45 patients
27 (60%) males. The positive cultures were from the antrum in
33 (73%) and body in 12 (27%). Fourteen (31%) were resistant
to clarithromycin and three (7%) to amoxicillin. All patients
completed treatment. Eighteen patients did not return for repeat
14
C-UBT to determine eradication status. Of the remaining 62
patients, 15 (24%) patients had a positive repeat 14C-UBT.
Conclusion. There was a high resistance to clarithromycin. Triple
therapy for 10 days was effective in two-third of the patients to
eradicate H. pylori.
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Abstract no.: 11.21
Role of Eradication of Helicobacter pylori
Infection in the Treatment of Functional
Dyspepsia
M. Ticak, M. Katicic, M. Prskalo, B. Skurla, T. Filipec
Kanizaj, B. Sabaric, V. Colic Cvrlje, S. Naumovski
Mihalic & B. Papa
University Hospital Merkur, Zagreb, Croatia
Aim. To ascertain the effect of eradication of Helicobacter pylori
infection on dyspeptic symptoms in patients with functional
dyspepsia (FD).
Material and Methods. The study included 140 patients with a
verified FD (according to the 1999 Rome Definition). Of 75 patients
with H. pylori infection, eradication therapy was performed in
68 patients (90% eradication success: 7-day therapy with
pantoprazole, amoxicillin, claritromycin), and 65 patients tested
negatively for H. pylori. All patients received pantoprazole for 4
weeks. Severity of dyspepsia was evaluated with the Nepean
Dyspepsia Index at baseline and after 1 month of treatment.
Statistical analysis was performed using analysis of variance.
Results. All three groups of patients with FD (H. pylori positive
eradicated, H. pylori positive noneradicated, and H. pylori negative)
demonstrated statistically significant decrease in dyspeptic symptoms
(p < .001). There was no statistically significant difference in
decrease in dyspeptic symptoms between the groups (p > .05).
Conclusion. Eradication of H. pylori infection in patients with FD
is not associated with a statistically significant decrease in
dyspeptic symptoms; patients with eradicated and noneradicated
H. pylori infection show a similar decrease. The presence of H.
pylori infection has no statistically significant influence on
decrease in dyspeptic symptoms in patients with FD, the patients
with noneradicated H. pylori infection and H. pylori-negative
patients report an approximately same decrease. Statistically
significant symptoms decrease in all three groups of patients is the
result of PPI therapy.
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Abstract no.: 11.22
The Effectiveness of Bismuth and Eupatilin
Along with Proton-Pump Inhibitor-Based
Triple Regimen in Eradication of
Helicobacter pylori
C. H. Lee,*† J. K. Lee,* J. W. Kim,* Y. S. Park,*†
N. Y. Kim,*† H. C. Jung,* I. S. Song* & D. H. Lee*†
*Seoul National University College of Medicine, Seoul, Republic of
Korea, †Seoul National University Bundang Hospital, Seongnam,
Republic of Korea
Background. Tripotassium dicitrato bismuth (Denol®) is an oral
bismuth agent used in quadruple regimen, and eupatilin
(Stillen®) is the extract of Artemisia asiatica Nakai. Eupatilin shows
anti-inflammatory and cytoprotective effect. We studied about
adding bismuth and eupatilin in triple regimen and its additional
effect in eradication of Helicobacter pylori.
Methods. This is a retrospective study about the eradication of H.
pylori in Bundang Seoul National University Hospital between
March 2005 and April 2006. H. pylori infection was confirmed by
endoscopic biopsy and CLO test. The eradication was assessed by
the 13C-urea breath test at 4 weeks after the end of treatment.
Results. Five hundred sixty-three patients were included and
total eradication rate is 76.7%. Two hundred ninety-six patients
treated with 1-week triple therapy (pantoprazole 40 mg,
amoxicillin 1000 mg, clarithromycin 500 mg, two times a day).
Their eradication rate was 77.4%. One hundred eighty-four
patients treated with lower-dose regimen (pantoprazole 40 mg,
amoxicillin 750 mg, clarithromycin 250 mg, two times a day).
This is a standard regimen in Japan. Their eradication rate was
74.5%. Between the two regimens, statistical significance did not
exist (p = .536). Forty-seven patients treated with adding bismuth
in lower-dose regimen. Their eradication rate was 74.5%. Thirtysix patients treated with adding eupatilin. Their eradication rate
was 86.1%. The eradication rate is higher, but there was no
statistical significance (p = .132)
Conclusion. Considering cost benefit and medication number,
lower-dose regimen (by Japanese guideline) is acceptable treatment
of H.r pylori in Korea. Eupatilin is a promising agent in H. pylori
eradication but more study will be needed.
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Abstract no.: 11.23
Do Proton Pump Inhibitor (PPI) Therapy before
Helicobacter pylori Eradication Inﬂuence on
the Eradication Rate? A Preliminary and Clinical
study
S. Kim, D. Lim, Y. Kim, T. Lee, E. Im, K. Huh, Y. Choi &
Y. Kang
Konyang University College of Medicine, Daejeon, Republic of
Korea
Introduction. The main factors affecting the outcome of
treatments for Helicobacter pylori infection were reported to be
antibiotic resistance and patient compliance. The other factors
were associated with age, gender, smoking, omeprazole, or H2
blocker pre-treatment. But it was not yet satisfactory reports
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about influence on eradication rate of the proton pump
inhibitor (PPI) therapy before H. pylori eradication. The aim of
this study was to determine influence on eradication rate of PPI
therapy.
Methods. From March 2004 to March 2006, Fifty-four patients
with peptic ulcer including ulcer scar at endoscopy and positive
result at the rapid urease test were enrolled. All infected patients
were given PPI-based 7-day regimen (omeprazole 20 mg b.i.d. or
lansoprazole 30 mg b.i.d., amoxicillin 1 g b.i.d., clarithromycin
500 mg b.i.d.). We included only patients with good drug
compliance. Eradication was assessed by urease breath test at
4 weeks after therapy.
Result. Fourty-two male and 12 female (mean age, 46 ± 14.5)
patients were enrolled. No pre-PPI group was 12 (22%) and prePPI therapy group was 42 (78%). H. pylori eradication rate of no
pre-PPI group was 91% on ITT analysis and pre-PPI group was
89.5%. There was no statistical significance in the two groups
(p = .80).
Conclusion. There was no significant difference in the H. pylori
eradication rate between no pre-PPI group and pre-PPI group. We
suggest that the PPI therapy before H. pylori eradication does not
influence on the eradication rate. More lager, randomized
controlled study was necessary.
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Abstract no.: 11.24
A New Curcumin-Based One-Week Triple
Therapy for Eradication of Helicobacter pylori
Infection: Something to Learn from a Failure?
L. G. Cavallaro,* A. Nouvenne,* G. Comparato,*
N. Stefani,* R. Merli,* V. Iori,* M. Martelli,† L. Martelli,†
G. M. Cavestro,* A. Franzè‡ & F. Di Mario*
*Department of Clinical Sciences, University of Parma, Italy,
†Department of Chemical Sciences, University of Padua, Italy,
‡Gastroenterology Unit, Hospital of Parma, Italy
Background. Curcumin is the principal element of turmeric
powder extract from Curcuma longa. Some studies showed actions
of curcumin against Helicobacter pylori infection. N-acetylcystein
and lactoferrin with mucolytic and antibacterial activities
respectively, could play important roles in H. pylori eradication
therapy.
Aim. To determine if a 7-day nonantibiotic therapy based on
curcumin, lactoferrin, N-acetylcystein, and pantoprazole is
effective on: (1) H. pylori eradication; (2) gastric inflammation
assessed by means of serum pepsinogens; (3) symptoms relief.
Materials and Methods. Twenty-five consecutive H. pylori-positive
patients (12 men, mean age 50 ± 12 years, range 31–76) with
functional dyspepsia were enrolled. Patients were administered
for 7 days: curcumin 30 mg b.i.d., bovine lactoferrin 100 mg b.i.d.,
N-acetylcystein 600 mg b.i.d., pantoprazole 20 mg b.i.d. H. pylori
status and upper GI symptoms were assessed and scored by means
of 13C-urea breath test and a Likert scale (absent, mild, moderate,
and severe) at baseline (T0) and after 2 months (T1), as well as
two blood tests (at T0 and T1) for serum pepsinogens (sPGI,
sPGII), gastrin-17 (G-17), and anti-Helicobacter IgG (IgG-H. pylori)
were performed.
Results. Three out of 25 patients (12%) were cured from H. pylori
infection. There was a significant decrease in the overall
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symptoms severity (T0: 6 ± 3; T1: 3 ± 2, p < .001), in sPGI (T0:
80 ± 26; T1: 74 ± 26, p = .02), and sPGII levels (T0: 19 ± 10;
T1: 12 ± 7, p < .001). IgG and G-17 values did not significantly
decrease after 2 months.
Conclusions. This novel therapy is not effective on H. pylori
eradication, but despite bacterium persistence seems to improve
dyspeptic symptoms as well as gastric inflammation.
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Abstract no.: 11.25
Brazilian Green Propolis on Helicobacter pylori
Infection. A Pilot Clinical Study
L. G. V. Coelho,* E. M. A. F. Bastos,† C. C. Resende,*
C. M. P. Silva,* B. S. F. Sanches,* F. J. Castro,*
L. D. Moretzsohn,* W. L. S. Vieira* &
O. R. Trindade*
*Federal University of Minas Gerais, Belo Horizonte, Brazil,
†Fundação Ezequiel Dias, Belo Horizonte, Brazil
Background. There is an increasing search for nonantibioticbased anti-Helicobacter pylori therapy. Recent in vitro studies
suggest that propolis and its phenolic components are able to
inhibit H. pylori growth. There are no clinical studies by now.
Aims. A pilot study to evaluate the effect of Brazilian green
propolis on H. pylori-infected individuals.
Patients and Methods. After informed consent, 11 (six women,
mean age 45 years) participants naive of previous anti-H. pylori
treatment were included. Before treatment, all participants were
submitted to gastroscopy, and H. pylori infection were confirmed
by histology, urease test, and 13C-urea breath test (UBT) (IRIS,
Wagner Analysen-Technik, Germany). Participants with UBT
showing a delta over baseline (DOB) value higher than 4‰ were
considered positive for H. pylori infection. Twenty drops from an
alcoholic preparation of Brazilian green propolis (FUNED, Brazil)
were administered three times a day for 7 days. Clinical evaluation
and UBT were performed at 1–3 days and at 40 days after therapy
to evaluate H. pylori suppression or eradication, respectively.
Results. All participants took all medication and completed the
study. Only two participants referred mild nausea with the
medication. One out 11 participants reached partial suppression
immediately after therapy and another participant eradicated
H. pylori infection 40 days after treatment.
Conclusions. Brazilian green propolis administered at popularly
used dosis showed minimal effect on suppression or eradication of
H. pylori infection. Further studies using larger dosis and longer
duration are needed to define an eventual role of Brazilian green
propolis on H. pylori therapy.
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Abstract no.: 11.26
Efﬁcacy of Esomeprazole and Rabeprazole for
Helicobacter pylori Eradication in Patients with
Peptic Ulcer

Abstract no.: 11.27
Norﬂoxacin-Bismuth Complexation: A Novel
Approach for Helicobacter Therapy
A. R. Shaikh,* M. R. Yadav* & V. S. Velingkar†

D. Kim
Seoul National University Hospital Gangnam Healthcare Center,
Seoul, Republic of Korea
Background/Aims. Esomeprazole, a new proton pump inhibitor
that is the S-isomer of omeprazole and produces a greater
inhibition of acid secretion than omeprazole, has recently been
evaluated in the treatment of Helicobacter pylori. However, the
clinical efficacy of esomeprazole-based triple therapy for Korean
patients is not well known. Thus, we assessed the efficacy of
esomeprazole-based triple therapy with H. pylori active peptic
ulcer.
Methods. Four hundred twenty-six patients (300 men, 126
women) were enrolled retrospectively to receive either regimen
EAC (esomeprazole 40 mg, clarithromycin 500 mg, amoxicilin
1 g, all twice daily) or RAC (rabeprazole 20 mg, clarithromycin
500 mg, amoxicilin 1 g, all twice daily) for 1 week. H. pylori infection
was confirmed by histology (Giemsa stain) after endoscopic
biopsy. H. pylori eradication rate was determined by urea breath
test 4–6 weeks after completion of the treatment.
Result. The overall eradication rate was 76.8% (327/426). H.
pylori eradication rate was 78.1% (178/228) in the EAC group and
75.3% (149/198) in the RAC group.
Conclusions. Esomeprazole-based triple therapy is effective for
the eradication of H. pylori infection and offers comparable
efficacy to rabeprazole-based therapy.

*Department of Pharmacy, M.S. University, Baroda, India,
†K. M. Kundnanai College of Pharmacy, Mumbai, India
Helicobacter pylori is a curved, spiral gram-negative motile
organism. It infects the gastric antrum and causes gastritis.
Helicobacter pylori infection results in an acute, then chronic,
inflammation of the gastric mucosa. The inflammation regresses
following antimicrobial treatment.
Helicobacter pylori is highly susceptible to bismuth, a heavy metal
with antimicrobial activity linked to its effect on bacterial iron
uptake. Despite these findings, bismuth monotherapy often fails
to completely eradicate these bacteria. A number of studies have
linked the antimicrobial activities of many heavy metals,
including bismuth, against Helicobacter.
Fluoroquinolones possess a broad spectrum of activity. They
show activity against a wide variety of aerobic gram-negative and
gram-positive bacteria. The mechanism of their action involves
inhibition of bacterial DNA gyrase, which is essential for DNA
replication, and it has been proposed that metal complex
intermediates are involved in this process.
Present work involved the synthesis of an organometallic
complex of norfloxacin with bismuth. The previously mentioned
complex was purified and characterized by various spectral
techniques like ultraviolet (UV), infrared (IR), nuclear magnetic
resonance (NMR), differential scanning calorimeter (DSC), and
atomic absorption spectrototometry (AAS). Preliminary antimicrobial
evaluation confirmed the activity of the synthesized complex
against various gram-negative and gram-positive organisms.
In vitro anti-H. pylori studies were performed and the MIC values
for the complex was determined. The complex was found to be
active against H. pylori with a MIC value of less than 0.25 µg/L.
Also, the activity was compared against the standard drugs
(norfloxacin alone and also with the bismuth salt alone).
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Abstract no.: 12.01
Deregulation of SHP-2 Affecting Signal
Transduction Switch by Helicobacter pylori
Oncoprotein CagA
I. Lee,* J. Kim,* E. Ryu,* Y. Choi,* J. Cheon,* Y. Lee,*
S. Kim† & M. Blaser‡
*Gastroenterology, Seoul, Republic of Korea, †College of
Medicine, Chungbuk, Republic of Korea, ‡New York University
School of Medicine, New York, NY, United States
Aims. Helicobacter pylori CagA is associated with gastric carcinoma.
It has been shown that phosphorylated CagA binds SHP2 and
affects signal transduction switch. In addition, it has been shown

that gp130, IL6 cytokine coreceptor, having a bifunctional
domain, leads to balanced signaling through SHP2/Erk and
STAT1/3 pathways. Therefore, the aims of this study were to
evaluate the effect of translocated CagA in the signal transduction
switch of gp130 and the role of tyrosine phosphorylation status
regarding signal talk between SHP2/Erk and STAT1/3 pathways.
Methods. We used a pair of naturally occurring cagA isogenic
mutants 147C and 147A. CagA expression vectors with or
without CagA tyrosine phosphorylation activities were used. We
performed immunoprecipitation assay to assessed the interaction
between CagA, SHP2, and/or gp130. We assessed activation of
STAT3 or Erk pathways,effect of bax and bcl-2 expression
according to cagA isogenic mutants.
Results. Phosphorylated CagA showed greater magnitude of
SHP2 binding activity, and SHP2 was recruited to gp130.
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